Pliant Therapeutics Inc (NASDAQ: PLRX) open the trading on Wednesday, with great promise as it jumped 4.41% to $2.72, before settling in for the price of $2.61 at the close. Taking a more long-term approach, PLRX posted a 52-week range of $2.60-$18.00.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
The company of the Healthcare sector’s yearbook sales growth during the past 5- year span was recorded -41.09%. Meanwhile, its Annual Earning per share during the time was -22.68%. Nevertheless, stock’s Earnings Per Share (EPS) this year is -32.09%. This publicly-traded company’s shares outstanding now amounts to $60.85 million, simultaneously with a float of $53.50 million. The organization now has a market capitalization sitting at $165.52 million. At the time of writing, stock’s 50-day Moving Average stood at $12.10, while the 200-day Moving Average is $12.63.
Pliant Therapeutics Inc (PLRX) Ownership Facts and Figures
Sometimes it helps to make our mind if we keep our tabs on how bigger investors are working with the stock of the Biotechnology industry. Pliant Therapeutics Inc’s current insider ownership accounts for 12.08%, in contrast to 95.94% institutional ownership. According to the most recent insider trade that took place on Jan 17 ’25, this organization’s President and CEO sold 52,419 shares at the rate of 11.20, making the entire transaction reach 587,150 in total value, affecting insider ownership by 430,517. Preceding that transaction, on Jan 17 ’25, Company’s Chief Financial Officer sold 20,148 for 11.20, making the whole transaction’s value amount to 225,680. This particular insider is now the holder of 262,608 in total.
Pliant Therapeutics Inc (PLRX) Earnings and Revenue Records
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.9 per share during the current fiscal year.
Pliant Therapeutics Inc’s EPS decrease for this current 12-month fiscal period is -32.09% and is forecasted to reach -3.78 in the upcoming year. Considering the longer run, market analysts have predicted that Company’s EPS will decrease by -9.81% through the next 5 years, which can be compared against the -22.68% growth it accomplished over the previous five years trading on the market.
Pliant Therapeutics Inc (NASDAQ: PLRX) Trading Performance Indicators
Let’s observe the current performance indicators for Pliant Therapeutics Inc (PLRX). It’s Quick Ratio in the last reported quarter now stands at 10.26. The Stock has managed to achieve an average true range (ATR) of 1.18.
In the same vein, PLRX’s Diluted EPS (Earnings per Share) trailing twelve months is recorded -3.34, a figure that is expected to reach -0.98 in the next quarter, and analysts are predicting that it will be -3.78 at the market close of one year from today.
Technical Analysis of Pliant Therapeutics Inc (PLRX)
[Pliant Therapeutics Inc, PLRX] recent stats showed that its last 5-days Average volume was superior the volume it posted in the year-ago period. During the previous 9 days, stock’s Stochastic %D was recorded 1.77% While, its Average True Range was 1.35.
Raw Stochastic average of Pliant Therapeutics Inc (PLRX) in the period of the previous 100 days is set at 2.12%, which indicates a major fall in contrast to 2.78% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 408.97% that was higher than 174.96% volatility it exhibited in the past 100-days period.
